Nona Biosciences, a wholly-owned subsidiary of
Through the collaboration, Nona Biosciences will provide Dragonfly Therapeutics with access to the HCAb technologies as well as antibody generation services for the targets designated by Dragonfly Therapeutics. Financial terms were not disclosed. The collaboration is Nona's follows a recently announced license and collaboration agreement with
Dr.
About HCAb
HCAb's patented technology generates novel 'heavy chain only' antibodies, which are about half the size of a typical IgG. These antibodies carry IgG-like PK properties and Fc-domain functions without the need for additional engineering or humanization. Lack of light chain also minimizes the issue of light chain mispairing and heterodimerization. These characteristics enable the development of products with attributes not achievable by conventional antibody platforms. In addition, HCAb-derived multiple novel therapeutic antibody modalities, including single-domain antibodies, bi-, and multi-specifics, antibody-drug conjugates, CAR-Ts, or VH domain-derived diagnostic or therapeutic products, are also achievable using this platform.
About Nona Biosciences
Nona Biosciences (a wholly-owned subsidiary of
Harbour Mice generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Integrating Harbour Mice and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. More information, please check www.nonabio.com
About Dragonfly Therapeutics
Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel bispecific antibody technology to harness the body's innate immune system to bring breakthrough treatments to patients. Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platform that is progressing toward the clinic, as well as productive collaborations with Merck, AbbVie, Gilead and
Contact:
Email: pr@harbourbiomed.com
(C) 2022 Electronic News Publishing, source